Literature DB >> 23864163

Tumor-specific T-cell help is associated with improved survival in melanoma.

Katherine Woods1, Jonathan Cebon.   

Abstract

Despite success with immune checkpoint inhibitors, clinical benefit from cancer vaccines remains elusive. Combined targeting of melanoma-specific CD4(+) and CD8(+) T-lymphocyte epitopes was associated with improved survival compared with targeting either alone, or when a nonspecific helper epitope was used. We discuss the potential role of antigen-specific CD4 help. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23864163     DOI： 10.1158/1078-0432.CCR-13-1349

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway.

Authors:  Teng-Fei Fan; Wei-Wei Deng; Lin-Lin Bu; Tian-Fu Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

2.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

3.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors:  Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

Review 4.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Authors:  Jeanne Galaine; Christophe Borg; Yann Godet; Olivier Adotévi
Journal:  Vaccines (Basel)       Date:  2015-06-30

5.  Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.

Authors:  Junji Yatsuda; Atsushi Irie; Kumiko Harada; Yayoi Michibata; Hirotake Tsukamoto; Satoru Senju; Yusuke Tomita; Akira Yuno; Masatoshi Hirayama; Mohammad Abu Sayem; Naoki Takeda; Isao Shibuya; Shinji Sogo; Fumihiro Fujiki; Haruo Sugiyama; Masatoshi Eto; Yasuharu Nishimura
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 6.  Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Authors:  Youra Kim; Derek R Clements; Andra M Sterea; Hyun Woo Jang; Shashi A Gujar; Patrick W K Lee
Journal:  Viruses       Date:  2015-12-09       Impact factor: 5.048

7.  Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Liang Mao; Teng-Fei Fan; Lei Wu; Guang-Tao Yu; Wei-Wei Deng; Lei Chen; Lin-Lin Bu; Si-Rui Ma; Bing Liu; Yansong Bian; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  J Cell Mol Med       Date:  2017-04-11       Impact factor: 5.310

Review 8.  Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.

Authors:  Wiktoria Blaszczak; Wojciech Barczak; Anna Wegner; Wojciech Golusinski; Wiktoria Maria Suchorska
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

9.  PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Lin-Lin Bu; Cong-Fa Huang; Wen-Feng Zhang; Wan-Jun Chen; J Silvio Gutkind; Ashok B Kulkarni; Zhi-Jun Sun
Journal:  Oncotarget       Date:  2015-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.